ADCS
Business Services · Virginia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
14002 Thunderbolt Pl, Chantilly, Virgini...Phone Number
(858) 848-2000Website
www.adcs.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About ADCS
ADCS Inc. is a leader in developing comprehensive enterprise solutions that encompass data capture and indexing, data conversion, and information management. The company is also at the forefront of creating advanced techniques and practices in information assurance, ensuring high levels of quality and security. ADCS aims to provide unparalleled service to its clients through innovative technology and strong core values. Their intended clients include organizations seeking robust data management and security solutions.Explore more
ADCS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ADCS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when ADCS launches new products
Check out if ADCS is spiking on competitors!
Earning: See what the market has to say on ADCS recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at ADCS
Website visits: Recent activity has been detected on your website
ADCS, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ADCS had a recent Job posting/layoffs
Funding: Get notified immidiatlly once ADCS has new funding data
Check if ADCS has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at ADCS
Find 2 more new buyers
Company Profile Activity
Activity Insights
ADCS is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ADCS is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ADCS.
ADCS Tech Stack
A closer look at the technologies used by ADCS
ADCS News & Media
ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced updated clinical data from its two lead programs, loncastuximab tesirine (Lonca) and camidanlumab tesirine (Cami), which were presented at the 62nd American Society of HematolADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refrADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights. “The third quarter was one of tremendous execution as we prepare forADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, November 12, 2020 at 8:30 am ET to report financial results for the third quarter ended September 30, 2020 a
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding ADCS
Sign Up For FreeTo access detailed company insights
ADCS Inc. is a leader in developing comprehensive enterprise solutions that encompass data capture and indexing, data conversion, and information management. The company is also at the forefront of creating advanced techniques and practices in information assurance, ensuring high levels of quality and security. ADCS aims to provide unparalleled ser... Read More
